Novartis Signs an Exclusive Research and Option to Acquire Agreement with IFM Due to Develop Therapies Targeting cGAS/STING Pathway

 Novartis Signs an Exclusive Research and Option to Acquire Agreement with IFM Due to Develop Therapies Targeting cGAS/STING Pathway

Novartis Signs an Exclusive Research and Option to Acquire Agreement with IFM Due to Develop Therapies Targeting cGAS/STING Pathway

Shots:

  • Novartis to get an option to acquire IFM Due (a subsidiary of IFM Therapeutics) in exchange of funding for research & development of cGAS/STING program. Post exercising of option, IFM to receive $840M including up front and other contingent consideration
  • IFM has two preclinical pipeline programs, first developing as oral STING antagonist having the ability for blocking excessive production of interferons & other pro-inflammatory cytokines, intended to enter into a clinical study in 2021 while the second as cGAS inhibitor blocking the pathway at the more upstream node
  • The cGAS/STING pathway functions within the innate immune system to sense cytosolic DNA, triggering STING-dependent inflammatory response to treat chronic inflammatory and autoimmune diseases

Click here to­ read full press release/ article | Ref: IFM Therapeutics | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post